Brookline Capital Acquisition Predicts Immunic FY2025 Earnings

Immunic, Inc. (NASDAQ:IMUX) – Analysts at Brookline Capital Acquisition issued their FY2025 EPS estimates for shares of Immunic in a research report issued on Tuesday, February 3rd. Brookline Capital Acquisition analyst F. Ahmed forecasts that the company will earn ($0.65) per share for the year. Brookline Capital Acquisition has a “Strong-Buy” rating on the stock. The consensus estimate for Immunic’s current full-year earnings is ($0.94) per share. Brookline Capital Acquisition also issued estimates for Immunic’s Q4 2025 earnings at ($0.12) EPS, Q1 2026 earnings at ($0.13) EPS, Q2 2026 earnings at ($0.12) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at ($0.10) EPS and FY2026 earnings at ($0.46) EPS.

Immunic (NASDAQ:IMUX) last released its quarterly earnings results on Thursday, November 13th. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.05.

Other equities research analysts have also issued reports about the stock. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Thursday, October 16th. Roth Mkm assumed coverage on shares of Immunic in a report on Friday, November 7th. They set a “buy” rating and a $3.00 price objective for the company. D. Boral Capital reiterated a “buy” rating and issued a $8.00 target price on shares of Immunic in a research report on Wednesday, January 7th. Weiss Ratings restated a “sell (e+)” rating on shares of Immunic in a research report on Monday, December 29th. Finally, HC Wainwright dropped their price target on Immunic from $10.00 to $8.00 and set a “buy” rating for the company in a research note on Friday, November 14th. Four analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, Immunic presently has a consensus rating of “Buy” and a consensus target price of $7.40.

Immunic Trading Up 5.3%

IMUX stock opened at $0.62 on Friday. The company’s 50 day moving average is $0.63 and its 200 day moving average is $0.77. The stock has a market cap of $74.58 million, a price-to-earnings ratio of -0.75 and a beta of 1.58. Immunic has a 1-year low of $0.51 and a 1-year high of $1.39.

Hedge Funds Weigh In On Immunic

A number of hedge funds have recently modified their holdings of the company. Qube Research & Technologies Ltd purchased a new stake in shares of Immunic during the third quarter worth about $29,000. Two Sigma Investments LP bought a new position in Immunic during the 3rd quarter valued at approximately $52,000. HB Wealth Management LLC bought a new position in Immunic during the 3rd quarter valued at approximately $81,000. Virtu Financial LLC purchased a new stake in Immunic in the 3rd quarter worth approximately $99,000. Finally, GSA Capital Partners LLP bought a new stake in shares of Immunic in the 3rd quarter worth approximately $170,000. Hedge funds and other institutional investors own 51.82% of the company’s stock.

Key Headlines Impacting Immunic

Here are the key news stories impacting Immunic this week:

• Positive Sentiment: Brookline Capital Management upgraded Immunic to a “Strong‑Buy” (reported by Zacks), a direct positive catalyst that can attract buyers and short‑covering. Zacks Upgrade
• Positive Sentiment: Brookline’s FY2026 outlook is materially less negative than the consensus — the firm forecasts FY2026 EPS of ($0.46) versus the street consensus of about ($0.94) — signaling an improving earnings trajectory that may be interpreted positively by investors. MarketBeat Report
• Neutral Sentiment: Brookline published detailed quarterly EPS forecasts (Q4 2025: -$0.12; Q1 2026: -$0.13; Q2 2026: -$0.12; Q3 2026: -$0.11; Q4 2026: -$0.10), providing investors with updated cadence for expected losses and potential milestones to watch. MarketBeat Forecasts
• Negative Sentiment: Despite the upgrade and smaller projected losses, Immunic remains unprofitable with consensus and Brookline forecasts still negative; the company’s small market cap, low share price and relatively thin liquidity increase execution and stock‑volatility risk for investors.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.